SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting
Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4th at 8:00 a.m. ET CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new data from the ongoing Phase 1 s
Tumor Microenvironment Partial Response Surface Oncology Pancreatic Cancer Lung Cancer Tumor Shrinkage
Source: yahoo.com